Edit |   |
---|---|
Antigenic Specificity | TROP2, Human |
Clone | REAL1238 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | n/a |
Format | phycoerythrin (PE) conjugate |
Size | 200 µL |
Concentration | n/a |
Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | TROP2 Antibody, anti-human, PE, REAdye_lease™. Clone REAL1238 is an antibody fragment derived from the full TROP2 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL1238 recognizes the human TROP2 antigen, a type I membrane glycoprotein also known as TACSTD2 (Tumor-associated calcium signal transducer 2). TROP2 acts as a signal transducer and may be involved in regulating the growth of carcinoma cells. TROP2 is strongly expressed by a variety of human carcinomas, but also on trophoblasts and epithelial cells. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
Immunogen | n/a |
Other Names | TACSTD2, GA733-1, M1S1, EGP-1 |
Gene, Accession # | n/a |
Catalog # | 130-130-217 |
Price | $460 |
Order / More Info | TROP2, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Fornaro, M. et al. (1995) Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int. J. Cancer 62 (5): 610-618. | Ripani, E. et al. (1998) Human Trop-2 is a tumor-associated calcium signal transducer. Int. J. Cancer 76 (5): 671-676. | Cubas, R. et al. (2010) Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol. Cancer 9: . | Shvartsur, A. et al. (2015) Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer 6 (3-4): 84-105. |